Log In
Print
BCIQ
Print
Print this Print this
 

Semaglutide, subcutaneous semaglutide (NN9535)

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionLong-acting human glucagon-like peptide-1 (GLP-1) analog
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase III
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Partner

Zosano Pharma Corp.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today